ArticleAdvanced materials (Deerfield Beach, Fla.)2026
Navigating Lipid Nanostructure Design Space Through Continuous Microfluidic Automation.
Article in Advanced materials (Deerfield Beach, Fla.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
The versatility of nanoscale lipid particles has positioned them as the scaffold of choice for biomedical delivery, synthetic membrane engineering, and fundamental biophysical exploration. Across these fields, rational particle design has become a major bottleneck. Lipid composition, stoichiometry, size, morphology, phase behavior, and biophysical properties combine into an enormous, high‑dimensional space that is inherently difficult to explore, making conventional optimization approaches slow and limited. Identifying optimal lipid compositions in this vast space necessitates high-throughput screening based on efficient low-cost automation. Here we introduce a high-throughput microfluidic platform for rapid screening of lipid nanoparticles, offering precise, programmable control over composition and morphology. The system integrates on-chip microfluidic metering of lipid stocks with continuous particle self-assembly, followed by robotic collection into 96-well plates. This workflow enables the generation of over 200 unique formulations per hour, delivering a several-orders-of-magnitude increase in throughput relative to conventional approaches. We apply the platform to systematically map biophysical space at unprecedented resolution, validate compositional trends in transfection efficiency, and identify non-lamellar formulations with optimal functional performance. By coupling scalable synthesis with automated screening, we expect this platform to provide a robust foundation for data-driven and AI-integrated discovery of self-assembled nanomaterials including lipid, polymeric, and biomolecular assemblies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.